BIRC5 and breast cancer: A screening of 1363 drugs in vitro in ten patient-derived TNBC cell lines identified that the combination of afatinib and YM155, an inhibitor of baculoviral IAP repeat-containing protein 5 (BIRC5; gene encoding survivin) expression [448], reduced the growth of patient-derived TNBC cells in vitro and the PDX mammary tumors in vivo [449].